Short interest spike weighs
NTLA is dropping sharply despite recent FDA acceptance for its lead gene therapy, as elevated short interest at over 40% creates persistent selling pressure that overwhelms the positive regulatory news.
Sources: https://www.quiverquant.com/news/Intellia+Therapeutics+Stock+Short+Interest+Rises+to+40.35%25, https://www.tradingview.com/news/tradingview:4c415af
Previous verdicts for NTLA
- AI Search: Barclays Underweight Initiation Pressures Intellia Therapeutics — 2026-10-06
- Commercial Caution — 2026-09-15
- Cathie Wood adds NTLA — 2026-09-14
- Short interest spike weighs — 2026-09-09
- Debt deal lifts stock — 2026-09-04
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works